Skip to content
HowShorted

HERON THERAPEUTICS, INC. short interest in 2018

In 2018, HERON THERAPEUTICS, INC.'s disclosed short interest ran from 13.94% of shares outstanding on 12 Jan 2018 to 15.77% on 31 Dec 2018, a change of +1.83 percentage points. The year's high was 15.77% on 31 Dec 2018 and its low 9.71% on 15 Feb 2018, averaging 12.55% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.17 days on 14 Dec 2018. Full history: HERON THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for HERON THERAPEUTICS, INC. in 2018

2018 in figures

Start of year
13.94% (12 Jan 2018)
End of year
15.77% (31 Dec 2018)
Change
+1.83 pp
High
15.77% (31 Dec 2018)
Low
9.71% (15 Feb 2018)
Average
12.55%
Highest days to cover
16.17 (14 Dec 2018)
SEC filings marked
9

Every report in 2018

HERON THERAPEUTICS, INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201813.94%7.03results (8-K)
31 Jan 201811.62%5.42
15 Feb 20189.71%8.29
28 Feb 201811.02%8.1310-K filed, results (8-K)
15 Mar 201812.11%6.46
29 Mar 201812.88%3.18
13 Apr 201814.48%6.77
30 Apr 201811.84%9.66
15 May 201811.49%8.7910-Q filed, results (8-K)
31 May 201811.63%10.21
15 Jun 201813.82%7.38
29 Jun 201811.17%2.57
13 Jul 201811.43%11.37
31 Jul 20189.93%8.77
15 Aug 20189.98%11.0310-Q filed, results (8-K)
31 Aug 20189.94%13.85
14 Sep 201810.55%10.31
28 Sep 201812.43%5.94
15 Oct 201813.86%10.48
31 Oct 201814.89%11.28
15 Nov 201815.72%11.7810-Q filed, results (8-K)
30 Nov 201815.40%11.72
14 Dec 201815.61%16.17
31 Dec 201815.77%12.37

See also: HERON THERAPEUTICS, INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.